Molly O'Shea × Brad Gerstner × Jason Chang × Rob Goldberg

Brad Gerstner is pushing a $100 coronary calcium CT scan as “the mammogram for the heart,” targeting 40 million annual scans and claiming 50,000 lives and $20 billion in government care costs could be saved.Half of heart-attack victims have normal cholesterol, while preventive-cardiology chiefs scan at 30 or 35 and target LDL below 40 after any non-zero score.He thinks Medicaid and Medicare coverage could arrive “by the end of this year,” but soft-plaque limits remain unresolved.

Lex Fridman × Andrew Scull

Psychiatry’s models face simultaneous strain after NIMH’s $20 billion genetics-and-neuroscience bet produced no improvement in patients’ lot.CATIE found newer antipsychotics no more efficacious than older drugs despite prices up to ten times higher, while SSRIs remain marginal.Big Pharma has retreated as new targets failed, leaving small startups and fragile evidence as the pipeline’s catalyst and risk.

Tess Cameron × Brian Skorney × Paul Matteis × Yaron Werber

HORIZON was “completely negative” despite pelacarsen reducing Lp(a) 80%, challenging biomarker shortcuts as Amgen fell 10% on read-through.Novartis’s Avidity failure less than a year after the $12 billion acquisition drove Artisan’s sales cut of about $5 billion and EPS CAGR to 4%.Dyne’s 25% placebo-adjusted CASI-22 splice correction and Roivant’s 56% PVR reduction set up catalysts, while endpoint and outcome risks remain.

Peter Diamandis × Martine Rothblatt

United Therapeutics has four thymus shots on goal, including an FDA-approved xenothymus program and newly acquired Thymmune, making thymic replacement Rothblatt’s “most practical pathway” to LEV in the 2030s.Its xeno-kidney trial is mid-flight, facilities are slated for Rochester in August and Houston in October, and xeno-heart moved to Phase 3 after two patients survived 60 days without heart failure, with IVIVA trials starting in 2028.

Jorge Conde × Stéphane Bancel

Moderna and Merck’s personalized mRNA cancer vaccine met its Phase 3 primary endpoint in melanoma and also hit distant metastasis-free survival at the first interim analysis, with patient availability hoped for in 2027.Phase 2 showed 50% five-year recurrence-free survival versus Keytruda alone and 80% disease-free; inside-cell antigen presentation and a Marlborough facility capable of tens of thousands of doses support scale, while pricing and 20% nonresponse remain watchpoints.

Daphne Zohar × Eric Schmidt × Sam Fazeli × Graig Suvannavejh

Biotech’s 80% XBI rally is structurally M&A-led, with roughly $138B announced against $59B of equity issuance, compressing premiums and leaving no preclinical IPOs.Moderna’s melanoma vaccine suggests a durable trade-secret franchise, while BioNTech’s colorectal failure leaves tumor context unresolved; daraxonrasib’s $478K price and frontline label, and ivonescimab’s HARMONi-3 in 6–9 months, set the key monitoring points.

Yushan × 英博

Moderna8月19日单日上涨177%，市场重估焦点转向肿瘤疫苗的增长与定价空间。INTerpath-001试验显示，个性化疫苗联合Keytruda的无复发生存达统计学显著；但OS、HR及亚组数据未披露，商业化仍取决于4至6周生产与耗材成本。

Ben Lamm × Molly O'Shea

Colossal’s woolly mice validated mammoth-editing in 30 days, with 100% healthy births and predicted phenotypes.With $635M raised, its screwworm solution could eradicate the problem in six to seven months versus $1.5B in taxpayer spending over eight years, pending permits.Astromec uses evolutionary-genomics AI for drug discovery; another extinct species may arrive within 12 months, but the target remains undisclosed.

Sarah Guo × Max Hodak

Prima won CE marketing approval in Europe in July, with commercial sales expected in coming weeks after trials let patients with macular degeneration complete Sudoku, crosswords, and read books.Science acquired Pixium’s Stanford-originated implant after about two years, calling it “by far the state-of-the-art”; pricing is unset, while future versions could improve color and expand the population from hundreds of thousands to millions.

李翔 × 夏宁

夏宁称，化学合成AI已达到“十年工作经验化学家”水平，五分钟可跑出客户耗时一两个月设计的路线。合成是DMTA循环瓶颈，若提速十到二十倍，新药和新材料研发通量或提高十到二十倍。商业化需白盒解释、验证和约束，并持续用智能调度压低token成本；SaaS与智能体将长期共存。